Company intelligence / Profile preview

Pluri Expert

Ownership: Private
Employees: ~112
Development stage: Other

Overview

Pluri has developed a proprietary 3D cell expansion platform enabling large-scale production of therapeutic cells. Its lead programs have advanced through clinical trials in indications such as muscle injury, acute radiation syndrome, and pre-eclampsia. The company also operates a GMP-certified manufacturing facility and offers CDMO services to external partners

Therapeutic areas: OtherRare DiseasesWomen's Health
Modalities: Cell therapyInduced pluripotent stem cell derived therapy
Industry: Biotech

Partnerships

Tnuva (cultivated meat collaboration)Remedy Cell and Kadimastem (CDMO agreements)other global food giants

Beyond the preview

Go deeper on Pluri Expert.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pluri Expert.

Explore the full profile